title: Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats.
abstract: We previously showed that chronic administration of the clinically atypical and clinically superior antipsychotic drug clozapine selectively reduces dopamine (DA) release in the nucleus accumbens but not neostriatum, and that this effect appears mediated by anatomically selective mesolimbic DA depolarization blockade. The present study extends that research to another mesocorticolimbic DA locus, the medial prefrontal cortex. Acute clozapine challenge (5-40 mg/kg i.p.) produced dose-dependent increased extracellular levels of DA and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), in the medial prefrontal cortex of awake, free-moving rats as measured by in vivo brain microdialysis. Chronic clozapine treatment (20 mg/kg/day for 21 days) did not significantly change basal extracellular levels of DA, DOPAC or HVA. Acute clozapine challenge on day 22 in the chronic clozapine-treated animals produced no significant differences in medial prefrontal cortex DA, DOPAC or HVA as compared to chronic vehicle-treated animals, indicating that tolerance to clozapine does not develop in the mesocortical DA system, in contrast to the mesolimbic system. The DA agonist apomorphine (100 micrograms/kg) produced decreased basal extracellular levels of DA, DOPAC and HVA in medial prefrontal cortex of both chronic clozapine-treated and chronic vehicle-treated rats.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neuroscience, Albert Einstein College of Medicine, New York, NY 10461.
authors.forename: J P
authors.initials: JP
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Ruan
authors.forename: W
authors.initials: W
authors.lastname: Paredes
authors.forename: E L
authors.initials: EL
authors.lastname: Gardner
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D003024:Clozapine / Q000008:administration & dosage / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D004334:Drug Administration Schedule; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007700:Kinetics; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014851:Wakefulness / Q000502:physiology
chemical_list: D015102:3,4-Dihydroxyphenylacetic Acid; D003024:Clozapine; D001058:Apomorphine; D004298:Dopamine; D006719:Homovanillic Acid